FDA Allows Outsourcing Facilities to Extend Beyond-Use Date for Repackaged Avastin

February 2, 2018: By Joan McKenna

Avastin is repackaged into smaller doses for IVT use.

The US FDA will allow outsourcing facilities to extend the beyond-use date (BUD) for repackaged Avastin if additional sterility testing is undertaken, the agency announced Jan. 19.

The FDA released the policy change in two published final guidance documents on compounding.

In response, the American Society of Cataract and Refractive Surgery said it was working with the ophthalmic community to identify the cost and time associated with the test and the opinions of outsourcers on the final guidance.

The current BUD for repackaged Avastin is 90 to 180 days, according to a Minnesota retina specialist.

Draft guidance released in February 2015 called for a BUD of no more than five days for biologics repackaged at 503B outsourcing facilities. The clock would start once the package was opened at an outsourcing facility for repackaging.

Critics said the short timetable would make it impossible for Avastin to be repackaged, labeled, shipped, handled, and used by a surgeon, much less tested for sterility.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility